2024
Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis
Musante K, Roome L, Yurtsever N, Rinder H, Tormey C, Lee E. Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis. American Journal Of Clinical Pathology 2024, 162: s147-s147. DOI: 10.1093/ajcp/aqae129.326.Peer-Reviewed Original ResearchSickle cell diseaseRed blood cell unitsSickle cell disease patientsRed blood cellsPatient's HctRBC unitsTransfused RBC unitsRetrospective chart reviewTwo-sample t-testChart reviewAdverse eventsMedian numberPre-procedureProphylactic procedureCell diseasePatientsAcademic hospitalAverage hematocritAverage HctBlood cellsHctTransfusion servicesT-testQuality studiesHematocritCharacterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States
Jacobs J, Booth G, Moise K, Adkins B, Bakhtary S, Fasano R, Goel R, Hinton H, Laghari S, Stephens L, Tormey C, Crowe E, Bloch E, Abels E. Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States. Transfusion 2024, 64: 1870-1880. PMID: 39248602, DOI: 10.1111/trf.18011.Peer-Reviewed Original ResearchRisk of HDFNAntigen testAntibody titersHemolytic diseaseRed blood cellsCell-free fetal DNA testingRisk of hemolytic diseaseCell-free fetal DNAMaternal antibody titersPregnant individualsFetal DNA testingBlood banksTransfusion medicine practiceFetal DNALaboratory testing practicesThird trimesterAntigen statusTransfusion medicine serviceAntigen resultsMedicine serviceFetusesHDFNCritical titerResponse rateDNA testing
2021
Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene
Manrai PA, Siddon AJ, Hager KM, Hendrickson JE, Keller MA, Tormey CA. Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene. Immunohematology 2021, 37: 109-112. PMID: 34591379, DOI: 10.21307/immunohematology-2021-015.Peer-Reviewed Original ResearchConceptsHigh-prevalence antigenReagent red blood cellsDirect antiglobulin testBlood samplesBlood group APatient blood samplesImmunohematology reference laboratoryRare alloantibodyRed blood cellsOncologic careAntiglobulin testGroup APolynesian descentBlood cellsNon-conservative amino acid changeSingle nucleotide variantsReference laboratoryAmino acid changesFamilial backgroundExon 8Antigen expressionExon 7Nucleotide variantsAcid changesExon 4Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola‐Visner M, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Study‐IV‐Pediatric F. Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2021, 61: 2589-2600. PMID: 34455598, DOI: 10.1111/trf.16626.Peer-Reviewed Original ResearchConceptsInternational normalized ratioBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIINational Heart LungTransfusion practicePediatric oncologyRecipient EpidemiologyHSCT patientsPlasma transfusionRed blood cellsPlatelet countHeart LungHematopoietic stem cell transplantation patientsHematopoietic stem cell transplant patientsMedian international normalized ratioStem cell transplant patientsStem cell transplantation patientsLower INR valuesPre-transfusion HbMedian platelet countMulticenter retrospective studyCell transplant patientsCell transplantation patientsStudy IIIAcute myeloid leukemia
2020
Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn
Gupta GK, Balbuena-Merle R, Hendrickson JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion And Apheresis Science 2020, 59: 102946. PMID: 32962917, DOI: 10.1016/j.transci.2020.102946.Peer-Reviewed Original ResearchConceptsRed blood cellsHemolytic diseaseCurrent pathophysiologic mechanismsSetting of pregnancyPeri-partum periodPregnant patientsRBC alloantibodiesPathophysiologic mechanismsTransfusion practiceAlloantibody detectionTransfusion therapyClinical impactAlloimmunizationTransfusion communityBlood bankPregnancyDeadliest formBlood cellsAlloantibodiesFetusesDiseaseLaboratory toolPatientsTherapySettingCOVID-19 and the Coombs test
Hendrickson JE, Tormey CA. COVID-19 and the Coombs test. Blood 2020, 136: 655-656. PMID: 32761221, PMCID: PMC7414592, DOI: 10.1182/blood.2020007483.Peer-Reviewed Original Research
2018
Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model.
Madrid DJ, Santhanakrishnan M, Liu J, Gibb DR, Liu D, Natarajan P, Beitler D, Shi Z, Mo C, Tormey CA, Patel SR, Stowell SR, Hendrickson JE. Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model. Blood Transfusion 2018, 17: 368-377. PMID: 30418129, PMCID: PMC6774925, DOI: 10.2450/2018.0178-18.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionBlood cell transfusionTransfusion of plateletsAlloimmune responseRed blood cellsCell transfusionWild-type recipientsBlood cellsImmune responseMurine modelRed blood cell alloimmunisationCD40/CD40L interactionHuman KEL glycoproteinWild-type C57BL/6Humoral immune responseAdaptive immune responsesDevelopment of alloantibodiesPlatelet-rich plasmaEndogenous plateletsCD40L interactionRecipient treatmentTransfusionDanger signalsCD40LTransgenic donors
2017
B cells require Type 1 interferon to produce alloantibodies to transfused KEL‐expressing red blood cells in mice
Gibb DR, Liu J, Santhanakrishnan M, Natarajan P, Madrid DJ, Patel S, Eisenbarth SC, Tormey CA, Stowell SR, Iwasaki A, Hendrickson JE. B cells require Type 1 interferon to produce alloantibodies to transfused KEL‐expressing red blood cells in mice. Transfusion 2017, 57: 2595-2608. PMID: 28836263, PMCID: PMC5745367, DOI: 10.1111/trf.14288.Peer-Reviewed Original ResearchConceptsBone marrow chimeric miceHuman KEL glycoproteinType 1 interferonB cellsMean fluorescence intensityChimeric miceRed blood cell antigensBlood cell antigensGerminal center B cellsWT B cellsRBC alloimmunizationIgG alloantibodiesAlloimmune responseB cell differentiationRed blood cellsTransfusion protocolControl miceInflammatory stateWT miceAutoimmune pathologyIgG productionIFNAR1 expressionPlasma cellsAntiviral immunityInflammatory stimuliIrradiation of Red Blood Cells and Alloimmunization
Tormey CA, Hendrickson JE. Irradiation of Red Blood Cells and Alloimmunization. Lab Medicine 2017, 48: 172-177. PMID: 28340248, DOI: 10.1093/labmed/lmx018.Peer-Reviewed Original ResearchConceptsAlloimmunization rateRBC alloimmunization rateTime of transfusionRBC unit transfusionPostoperative bleedingRed blood cell damageRed blood cellsRBC transfusionCommon diagnosisImmunosuppressive disordersTransfusion recipientsBlood cell damageAnimal modelsStudy subjectsTransfusionControl groupRBC antigensAntibody screeningRBC unitsPatientsBlood cellsCell damageRBCsOxidative damageDiagnosis
2016
Understanding red blood cell alloimmunization triggers
Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology 2016, 2016: 446-451. PMID: 27913514, PMCID: PMC6142457, DOI: 10.1182/asheducation-2016.1.446.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRed blood cellsRisk factorsBlood cellsWhite blood cellsBlood group antigensPregnancy outcomesAlloantibody formationRBC alloantibodiesRBC transfusionRecipient factorsTransfusion safetyAlloimmunizationAnimal modelsHuman studiesPrevention strategiesDonor plasmaDanger signalsParticular antigenGroup antigensAntigenTransfusionPregnancyNonrespondersCellsThe Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice
Gibb DR, Calabro S, Liu D, Tormey CA, Spitalnik SL, Zimring JC, Hendrickson JE, Hod EA, Eisenbarth SC. The Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice. EBioMedicine 2016, 9: 77-86. PMID: 27345021, PMCID: PMC4972549, DOI: 10.1016/j.ebiom.2016.06.008.Peer-Reviewed Original ResearchConceptsRBC transfusionNLRP3 inflammasomeRed blood cell transfusionInnate immune cell activationPro-inflammatory pathogensMolecular patternsBlood cell transfusionProduction of alloantibodiesTransfusion-associated mortalityImmune cell activationInnate immune stimuliBlood group antigensBone marrow failureAlloantibody productionRBC alloimmunizationAlloantibody responsesCell transfusionAlloimmune responseRed blood cellsABO matchingImmunological factorsInflammatory conditionsLeading causeImmune stimuliEndogenous DAMPBridging channel dendritic cells induce immunity to transfused red blood cells
Calabro S, Gallman A, Gowthaman U, Liu D, Chen P, Liu J, Krishnaswamy JK, Nascimento MS, Xu L, Patel SR, Williams A, Tormey CA, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE, Stowell SR, Eisenbarth SC. Bridging channel dendritic cells induce immunity to transfused red blood cells. Journal Of Experimental Medicine 2016, 213: 887-896. PMID: 27185856, PMCID: PMC4886363, DOI: 10.1084/jem.20151720.Peer-Reviewed Original ResearchConceptsSplenic dendritic cellsDendritic cellsRBC transfusionT cellsImmune responseRed blood cell transfusionBlood cell transfusionT cell primingConventional dendritic cellsDetrimental immune responsesB cell responsesNaive T cellsT cell helpMurine transfusion modelRBC transfusion supportTime of transfusionRBC alloantigensCell transfusionDC subsetsAllogeneic RBCsRed blood cellsRenal failureTransfusion supportMajor complicationsCell priming
2015
Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells
Tormey CA, Santhanakrishnan M, Smith NH, Liu J, Marschner S, Goodrich RP, Hendrickson JE. Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion 2015, 56: 863-872. PMID: 26643781, DOI: 10.1111/trf.13432.Peer-Reviewed Original ResearchConceptsWhite blood cellsFresh whole bloodPathogen reduction treatmentAlloimmune responseWhole bloodRBC antigensSyngeneic RBCsNegative direct antiglobulin testBlood cellsRBC antigen expressionRecipient alloimmune responsesDirect antiglobulin testMurine red blood cellsPathogen inactivation treatmentPosttransfusion RBC recoveryKEL RBCsRBC alloimmunizationImmunogenic neoantigensRed blood cellsAntiglobulin testBlood donorsImmune responseAntigen expressionHours posttransfusionHuman antigensMeasuring the influence of blood component infusion rate on recipient vital signs
Gehrie EA, Hendrickson JE, Tormey CA. Measuring the influence of blood component infusion rate on recipient vital signs. Vox Sanguinis 2015, 109: 353-358. PMID: 26174450, DOI: 10.1111/vox.12310.Peer-Reviewed Original ResearchConceptsRed blood cellsInfusion rateVital signsBlood pressurePulse rateBlood product volumeClose patient monitoringEvidence-based guidelinesBlood component administrationFaster infusion rateRoutine transfusionTransfusionMultispecialty hospitalHospital wardsHealthcare providersHospital unitsInfusion timeBlood componentsBlood cellsInfusionPlateletsPatient monitoringSignsSignificant changes
2014
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfusion Medicine And Hemotherapy 2014, 41: 420-429. PMID: 25670929, PMCID: PMC4280450, DOI: 10.1159/000369109.Peer-Reviewed Original ResearchRed blood cellsPatient populationInfluence of ClinicalDevelopment of antibodiesImportant clinical consequencesDiverse patient populationsBlood group antigensRBC alloimmunizationChronic transfusionRBC alloantibodiesHyper respondersClinical circumstancesClinical consequencesAlloimmunizationMedical literatureTransfusionAlloantibodiesGroup antigensRespondersBlood cellsTransfusion medicinePatientsBiological factorsIndividualsPregnancyThe Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital
Gehrie EA, Tormey CA. The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital. Military Medicine 2014, 179: 1099-1105. PMID: 25269127, DOI: 10.7205/milmed-d-14-00045.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood BanksBlood Grouping and CrossmatchingBlood Loss, SurgicalBlood TransfusionClinical AuditClinical ProtocolsConnecticutEmergenciesErythrocyte TransfusionFactor VIIaFactor VIIIFibrinogenHematemesisHospitals, VeteransHumansLaboratories, HospitalMalePlasma ExchangePlatelet TransfusionPostoperative HemorrhageRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsConceptsFresh frozen plasmaRecombinant factor VIIaRed blood cellsVeterans Affairs hospitalTransfusion protocolFactor VIIaUnits of RBCsVeterans Affairs Connecticut Healthcare SystemUnits of FFPLarge trauma centersHospital-based blood banksETP patientsMassive transfusionTrauma centerFrozen plasmaSeparate patientsPatientsWest HavenBleeding emergenciesBlood bankBlood cellsYears' experienceHealthcare systemPlateletsHospital
2013
Limiting the Extent of a Delayed Hemolytic Transfusion Reaction With Automated Red Blood Cell Exchange
Tormey CA, Stack G. Limiting the Extent of a Delayed Hemolytic Transfusion Reaction With Automated Red Blood Cell Exchange. Archives Of Pathology & Laboratory Medicine 2013, 137: 861-4. PMID: 23721278, DOI: 10.5858/arpa.2012-0154-cr.Peer-Reviewed Original ResearchConceptsRed blood cell exchangeHemolytic transfusion reactionsDAT resultsTransfusion reactionsDirect antiglobulin test resultsCell exchangeIncompatible red blood cellsSymptoms of hemolysisRed blood cell unitsPositive antibody screenBlood group antibodiesAntigen-negative unitsAnamnestic increaseAntigen reexposureFurther hemolysisRed blood cellsAntibody screenGroup antibodiesPatient historyBlood cellsDHTRTransfusionHemolysisSymptomsCell units
2011
Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity
Hendrickson JE, Hod EA, Cadwell CM, Eisenbarth SC, Spiegel DA, Tormey CA, Spitalnik SL, Zimring JC. Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion 2011, 51: 2445-2454. PMID: 21569043, PMCID: PMC3175302, DOI: 10.1111/j.1537-2995.2011.03162.x.Peer-Reviewed Original ResearchConceptsProinflammatory cytokine stormRed blood cellsHeat-treated red blood cellsFresh red blood cellsCytokine stormRBC clearanceAntigen expressionRapid clearanceBlood cellsAdverse transfusion outcomesFlow cytometric crossmatchChemoattractant protein-1Control red blood cellsDonor red blood cellsMurine red blood cellsStored red blood cellsTransgenic antigensCytometric crossmatchCytokine responsesRecipient miceInterleukin-6Transfusion outcomesHours posttransfusionHeat treatmentFourteen days
2010
In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system
Snyder EL, Whitley P, Kingsbury T, Miripol J, Tormey CA. In vitro and in vivo evaluation of a whole blood platelet‐sparing leukoreduction filtration system. Transfusion 2010, 50: 2145-2151. PMID: 20497514, DOI: 10.1111/j.1537-2995.2010.02701.x.Peer-Reviewed Original ResearchConceptsRed blood cellsWhite blood cellsAutologous plateletsTransfusion productsBlood cellsAdverse clinical sequelaeCPD plasmaProduction of plateletsResidual white blood cellsClinical sequelaeDrug Administration requirementsHospital useVivo efficacyLeukoreduction filtersBlood centersStudy designVivo evaluationLR productsVivo characteristicsPlateletsRBC recoveryAdministration requirementsVitroSurvival ratioFDA guidelines